Drug Profile
PF 3526299
Alternative Names: PF-03526299; PF-3526299Latest Information Update: 01 Jun 2011
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 27 Sep 2010 Phase-I development is ongoing
- 28 Feb 2008 Phase-I clinical trials in Asthma in USA (Inhalation)